Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2023-04-17 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (from 2.17% to 3.34%) held by DWS Investment GmbH due to 'Equity collateral received'. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns best with the Major Shareholding Notification (MRQ) category. Although the header mentions 'Voting Rights Announcements', the content structure and purpose match the MRQ definition more precisely than DVA (which is for voting results) or DIRS (which is for director trades).
2023-04-17 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections like 'Notification of Major Holdings', specifying changes in voting rights percentages (e.g., 6.13% direct, 2.45% through instruments) held by JPMorgan entities in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This content directly matches the definition of reporting changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although the header mentions 'Voting Rights Announcements', the core content is the disclosure of major shareholdings.
2023-04-17 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, voting rights attached to shares, and rights through financial instruments, referencing specific German securities law (Article 40, Section 1 of the WpHG). This structure perfectly matches the definition of a notification regarding changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal disclosure of holdings by an entity (The Goldman Sachs Group, Inc.), making MRQ the most precise fit over DVA (which is for voting results) or DIRS (which is for director's personal trades).
2023-04-17 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It reports a change in the percentage of voting rights held by DWS Investment GmbH, specifically noting the reason as 'Equity collateral returned.' This directly corresponds to the definition of reporting changes in significant share ownership thresholds, which aligns best with the Major Shareholding Notification (MRQ) category. Although it mentions 'Voting Rights Announcements' in the header, the content is a specific regulatory filing about shareholding changes, not general voting results (DVA) or a general regulatory filing (RNS).
2023-04-17 English
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)
Earnings Release Classification · 1% confidence The document is dated April 16, 2023, and is presented as a 'Media Release' announcing 'Five-Year Results of L-MIND Study' for the drug Monjuvi®. It details clinical trial outcomes (ORR, CR, median duration of response, survival data) and safety profiles, which are typical components of an Earnings Release (ER) or a detailed announcement accompanying clinical data presentation. Since it focuses on announcing specific, periodic financial/clinical results (even if clinical data driven, it's a major corporate update) rather than being a full annual report (10-K), a comprehensive interim report (IR), or a transcript (CT), the most fitting category is Earnings Release (ER), as these announcements often precede or accompany formal quarterly reporting periods, focusing on key performance indicators (in this case, drug efficacy milestones). However, given the context is a press release announcing clinical data presented at a medical conference (AACR), and it is not explicitly tied to a standard quarterly financial reporting period (like Q1, Q2, etc.), it functions as a significant corporate/clinical update. If the document were purely a summary of financial performance, ER would be perfect. Since it is a detailed announcement of study results, it is a major corporate disclosure. In many databases, major clinical trial result announcements that are not part of a formal quarterly filing are often categorized as Regulatory Filings (RNS) or sometimes Investor Presentations (IP) if it were the slides themselves. Since this is a news release format detailing results, and it's not a standard financial report, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses ERs for major clinical milestones. Given the structure and content (announcing key data points and safety), ER is a strong candidate, but RNS is the safest fallback for non-standard, material announcements. Let's re-evaluate against the definitions. It is not a 10-K, AR, IR, CT, or DEF 14A. It is a major announcement. Since it is a news release format announcing material clinical data, and not a formal financial report, RNS (Regulatory Filings/General Announcement) is appropriate, but ER (Earnings Release) often covers major operational milestones that impact future earnings. Given the high detail on efficacy and safety, it leans towards a major operational update often bundled with ERs. I will select ER as it communicates performance milestones, even if clinical rather than purely financial, as it is a structured announcement. Upon final review, this is a press release announcing clinical trial results, not a formal financial report (like 10-K or IR) or a transcript. It is a material corporate announcement. RNS is the best fit for material, non-standard announcements, but ER is used for periodic results. Since this is a specific, dated announcement of study results, RNS is the most accurate catch-all for material news that isn't a standard financial report. Q4 2022
2023-04-16 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing the acquisition/disposal of shares with voting rights, specific ISINs, and the resulting percentage changes for the reporting entity (JPMorgan Chase & Co.) in MorphoSys AG. This content directly corresponds to the definition of reporting changes in significant share ownership thresholds. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2023-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.